Timothy Williams Sells 42,434 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) SVP Timothy Williams sold 42,434 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $8.27, for a total value of $350,929.18. Following the sale, the senior vice president owned 377,450 shares in the company, valued at approximately $3,121,511.50. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $7.91 on Friday. The firm has a 50 day moving average of $7.58 and a 200-day moving average of $5.99. The firm has a market capitalization of $467.56 million, a P/E ratio of -2.12 and a beta of 0.55. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $9.60. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The firm had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%. As a group, sell-side analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on VNDA. Jefferies Financial Group raised their price target on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. Zacks Research cut shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 18th. B. Riley Financial raised their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, December 31st. UBS Group reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vanda Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $14.90.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds have recently bought and sold shares of VNDA. Stonepine Capital Management LLC grew its position in Vanda Pharmaceuticals by 611.3% during the second quarter. Stonepine Capital Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock valued at $1,180,000 after acquiring an additional 214,852 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Vanda Pharmaceuticals by 96.5% in the 2nd quarter. Squarepoint Ops LLC now owns 153,345 shares of the biopharmaceutical company’s stock worth $724,000 after acquiring an additional 75,295 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 7.7% in the 2nd quarter. Kennedy Capital Management LLC now owns 237,468 shares of the biopharmaceutical company’s stock valued at $1,121,000 after purchasing an additional 17,020 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 4.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock valued at $7,986,000 after purchasing an additional 77,997 shares in the last quarter. Finally, Readystate Asset Management LP bought a new position in shares of Vanda Pharmaceuticals during the 3rd quarter valued at $138,000. Institutional investors own 88.14% of the company’s stock.

More Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Truist initiated coverage with a “Buy” and an $18 price target (roughly double current levels), a prominent bullish read that can attract buyers and trading volume. Truist starts Vanda at Buy $18 (Benzinga)
• Positive Sentiment: HC Wainwright reiterated a Buy and published detailed 2027 quarterly EPS forecasts plus a $24 price target — another high upside projection that supports constructive sentiment among growth/biotech investors. HC Wainwright issues estimates, Buy $24 PT
• Positive Sentiment: Regulatory procedure win: the FDA granted a formal evidentiary public hearing on the CDER refusal for Vanda’s sNDA for HETLIOZ in jet‑lag disorder — an uncommon, high‑visibility forum that could improve approval odds if Vanda presents a strong case. Vanda Announces FDA Grants Landmark Hearing for HETLIOZ (PR Newswire)
• Neutral Sentiment: Analyst landscape is mixed: several firms maintain Buy/Overweight calls and high targets (average ~$14.90), but ratings are not unanimous — constructive overall but not a consensus blowout. MarketBeat analyst summary
• Neutral Sentiment: HC Wainwright’s EPS cadence (quarterly 2027 estimates) gives a clearer path for modeling cash burn and potential milestones, useful for valuation but not an immediate catalyst by itself. HC Wainwright research note (MarketBeat)
• Negative Sentiment: Coordinated insider selling: CEO Mihael Polymeropoulos, CFO Kevin Moran, CMO Joakim Wijkstrom and multiple SVPs disclosed substantial sales on/around March 2 (combined proceeds in the low‑millions), which often pressures shares and triggers investor concern about insiders reducing exposure. Vanda’s Top Brass Quietly Unload a Wave of Shares (TipRanks)
• Negative Sentiment: SEC filings now formalize the insider transactions (individual ownership reductions 5–10% for some officers), removing ambiguity about size and timing and increasing short‑term selling pressure as investors parse motives (tax planning vs. signal). SEC filing — CEO ownership disclosure

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.